Dolutegravir plus darunavir maintains viral suppression without NRTIs
Majority of US young adults who use drugs are not tested for hepatitis C or HIV
Studies confirm long-term effectiveness of new single-tablet regimens
Efavirenz, but not dolutegravir, linked to neurological problems in children
Another rare PrEP failure reported in San Francisco
Doravirine combination works well as a switch option
